BACKGROUND: Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema). METHODS: Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were developed as a potential therapy for treatment of human eczema vaccinatum. RESULTS: Using a small animal model of eczema vaccinatum, we demonstrated that both murine and fully human monoclonal antibodies effectively limited eczema vaccinatum disease, foreshortening both the disease kinetics and the severity of the erosive viral skin lesions. CONCLUSIONS: These neutralizing antibodies would likely be effective at reducing or eliminating clinical disease in people with eczema vaccinatum or other severe side effects of the smallpox vaccine.
BACKGROUND:Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema). METHODS: Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were developed as a potential therapy for treatment of humaneczema vaccinatum. RESULTS: Using a small animal model of eczema vaccinatum, we demonstrated that both murine and fully human monoclonal antibodies effectively limited eczema vaccinatum disease, foreshortening both the disease kinetics and the severity of the erosive viral skin lesions. CONCLUSIONS: These neutralizing antibodies would likely be effective at reducing or eliminating clinical disease in people with eczema vaccinatum or other severe side effects of the smallpox vaccine.
Authors: Megan M McCausland; Mohammed Rafii-El-Idrissi Benhnia; Lindsay Crickard; John Laudenslager; Steven W Granger; Tomoyuki Tahara; Ralph Kubo; Lilia Koriazova; Shinichiro Kato; Shane Crotty Journal: Antivir Ther Date: 2010
Authors: Zhaochun Chen; Patricia Earl; Jeffrey Americo; Inger Damon; Scott K Smith; Yi-Hua Zhou; Fujuan Yu; Andrew Sebrell; Suzanne Emerson; Gary Cohen; Roselyn J Eisenberg; Juraj Svitel; Peter Schuck; William Satterfield; Bernard Moss; Robert Purcell Journal: Proc Natl Acad Sci U S A Date: 2006-01-25 Impact factor: 11.205
Authors: H Matsuda; N Watanabe; G P Geba; J Sperl; M Tsudzuki; J Hiroi; M Matsumoto; H Ushio; S Saito; P W Askenase; C Ra Journal: Int Immunol Date: 1997-03 Impact factor: 4.823
Authors: Mansun Law; Gemma C Carter; Kim L Roberts; Michael Hollinshead; Geoffrey L Smith Journal: Proc Natl Acad Sci U S A Date: 2006-04-03 Impact factor: 11.205
Authors: Stephanie R Monticelli; Peter Bryk; Matthew G Brewer; Hector C Aguilar; Christopher C Norbury; Brian M Ward Journal: PLoS Pathog Date: 2021-12-28 Impact factor: 6.823
Authors: Michael H Matho; Andrew Schlossman; Xiangzhi Meng; Mohammed Rafii-El-Idrissi Benhnia; Thomas Kaever; Mark Buller; Konstantin Doronin; Scott Parker; Bjoern Peters; Shane Crotty; Yan Xiang; Dirk M Zajonc Journal: PLoS Pathog Date: 2015-09-01 Impact factor: 6.823